CN114796283B - Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition - Google Patents
Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition Download PDFInfo
- Publication number
- CN114796283B CN114796283B CN202210525727.6A CN202210525727A CN114796283B CN 114796283 B CN114796283 B CN 114796283B CN 202210525727 A CN202210525727 A CN 202210525727A CN 114796283 B CN114796283 B CN 114796283B
- Authority
- CN
- China
- Prior art keywords
- cereal
- extract
- amino acid
- insect
- worm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 147
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 208000010643 digestive system disease Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims abstract description 76
- 241000238631 Hexapoda Species 0.000 claims abstract description 58
- 108010060231 Insect Proteins Proteins 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 208000011140 intestinal infectious disease Diseases 0.000 claims abstract description 11
- 230000003612 virological effect Effects 0.000 claims abstract description 11
- 208000004232 Enteritis Diseases 0.000 claims abstract description 10
- 208000008469 Peptic Ulcer Diseases 0.000 claims abstract description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 9
- 208000011906 peptic ulcer disease Diseases 0.000 claims abstract description 9
- 235000013339 cereals Nutrition 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000004570 mortar (masonry) Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108010039627 Aprotinin Proteins 0.000 claims description 4
- 238000000944 Soxhlet extraction Methods 0.000 claims description 4
- 229960004405 aprotinin Drugs 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 241000202815 Chrysomya megacephala Species 0.000 claims description 3
- 241000736227 Lucilia sericata Species 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000001079 digestive effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 25
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 239000003960 organic solvent Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 18
- 210000003608 fece Anatomy 0.000 description 14
- 206010012735 Diarrhoea Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 241000702670 Rotavirus Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 7
- 101800002372 Motilin Proteins 0.000 description 7
- 102000002419 Motilin Human genes 0.000 description 7
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 7
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000002301 combined effect Effects 0.000 description 4
- 201000005917 gastric ulcer Diseases 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- IKGXLCMLVINENI-QOXGANSBSA-M [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC Chemical compound [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC IKGXLCMLVINENI-QOXGANSBSA-M 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000037308 hair color Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960002088 pinaverium bromide Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical group N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 241001439624 Trichina Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 201000010582 ecthyma Diseases 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 201000000117 functional diarrhea Diseases 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 241000191839 Chrysomya Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000257162 Lucilia <blowfly> Species 0.000 description 1
- 241000920471 Lucilia caesar Species 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 241000192656 Nostoc Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000190079 Turnera Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
The invention belongs to the technical field of traditional Chinese medicine and digestive system disease treatment, and in particular relates to application of a five-cereal worm extract in preparing a medicine for treating digestive diseases and a pharmaceutical composition. The invention provides the application of the five-cereal insect protein extract and the five-cereal insect amino acid in treating peptic ulcer, irritable bowel syndrome, bacterial enteritis and viral enteritis, and has definite efficacy, safety and reliability. Wherein, the extraction process of the five-cereal insect protein extract and the five-cereal insect amino acid is not treated by an organic solvent, and the five-cereal insect protein extract and the five-cereal insect amino acid are not polluted by toxic reagents, are safe and harmless, and belong to pure natural preparations; meanwhile, the components of the pharmaceutical composition are mainly natural proteins and amino acids, so that the pharmaceutical composition has no toxic or side effect and does not produce adverse reaction.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine and digestive system disease treatment, and in particular relates to application of a five-cereal worm extract in preparing a medicine for treating digestive diseases and a pharmaceutical composition.
Background
The five-cereal insect is larvae of Lucilia sericata, chrysomya megacephala or other closely related insects in the family of the blowfly. According to the records of Chinese medicinal books of Ben Cao Ji Yu and Ben Cao Ji, five cereal worms are cold in nature and nontoxic, enter spleen and stomach meridians. The medicinal value of the five-cereal insects is found to be over 500 years in China, and the five-cereal insects can be used for external application after being dried and ground in the aspect of surgical treatment, and can treat infectious surgical diseases such as ecthyma, pustule on lips, carbuncle and the like. The "true materia medica" records "treating ecthyma". The Chinese medicinal materials Zhi (Zhi) and Chinese animal medicine (Zhi Shen Yao) and northeast animal medicine (Zhi Shen Yao) are all received by the name of five cereals. Several centuries ago, the native, indian, maya of australia used five-cereal insects to treat traumatic infections, and the last century in the thirty years, and united states surgeons used five-cereal insects to successfully treat myelitis, and five-cereal insect therapies have been increasingly popularized and applied. In recent years, western scholars and Chinese scholars have achieved good effects in treating wound surface infection by applying the live and dry powder of the five-cereal worms. The composition researches show that the five-cereal insect contains 62% of protein, 11% of fat mass fraction, 16% of chitosan, 18% of amino acid and 0.264% of antibacterial peptide mass fraction.
In terms of internal medicine treatment, yuan nan Ben Cao (Yunnan herbal medicine) records that five cereal worms have the effects of clearing heat and detoxicating, promoting digestion and strengthening spleen and stomach and are mainly used for treating dyspepsia and infantile malnutrition. Wang Yujiao et al report in "regulating action of five cereal insect powder on intestinal flora of mice" the regulating action of five cereal insect powder on intestinal flora of normal mice and functional diarrhea mice, and treat intestinal flora imbalance with five cereal insects. These reports are focused on the treatment of dyspepsia and functional diarrhea, and meanwhile, only the action of the five-cereal worm powder is concerned, and the problems of rough preparation method, undefined active ingredients and the like exist.
At present, the clinical treatment schemes for treating digestive diseases such as peptic ulcer, irritable bowel syndrome, bacterial enteritis, viral enteritis and the like mainly comprise chemical medicines, antibiotics and antiviral medicines, have certain side effects, and the problems of antibiotic resistance, virus variation and the like seriously afflict patients and clinicians. Development of digestive diseases treatment medicine with small toxic and side effects, less adverse reactions and wide application range is a real problem which needs to be solved in clinic urgently.
The invention patent with the publication number of CN 110279720A claims a five-cereal worm processed product and application thereof in regulating intestinal flora, and discloses that the five-cereal worm processed product is prepared by adopting chitinase and alkaline protease to treat five-cereal worm bodies, and the five-cereal worm coarse powder is prepared for regulating the intestinal flora, but is only applied to digestive diseases caused by exogenous pathogenic microorganisms, and cannot treat digestive diseases caused by conditional pathogenic bacteria or viruses.
Disclosure of Invention
The invention aims to provide application of a five-cereal worm extract in preparing a medicament for treating digestive diseases, and overcome the technical problems in the prior art.
Another object of the present invention is to provide a pharmaceutical composition, which has no toxic side effects and does not cause adverse reactions.
Therefore, the technical scheme provided by the invention is as follows:
Application of Valley insect extract in preparing medicine for treating digestive diseases is provided.
The five-cereal insect extract is a five-cereal insect protein extract and/or a five-cereal insect amino acid extract, the mass fraction of total protein in the five-cereal insect protein extract is 35-90%, and the mass fraction of total amino acid in the five-cereal insect amino acid extract is 40-95%.
The digestive diseases are peptic ulcer, irritable bowel syndrome, bacterial enteritis or viral enteritis.
The mass ratio of the five-cereal insect protein extract to the five-cereal insect amino acid extract is 1:1-2.
The five cereal insect protein extract or/and the five cereal insect amino acid extract are mixed with other active ingredients (such as five cereal insect chitosan) and auxiliary materials to prepare the oral preparation.
The preparation process of the five-cereal insect protein extract comprises the following steps:
Putting 5g of aseptic maggot larva into a mortar, adding 3mL of liquid nitrogen, fully grinding, adding 5mL of water solution containing 0.1 mug/mL aprotinin and 0.1% trifluoroacetic acid, fully grinding, centrifuging the homogenate at 4 ℃ for 30min after being subjected to light-proof ice bath for 60min at the speed of 20000r/min, collecting supernatant, heating in a boiling water bath for 10min, centrifuging at 4 ℃ for 30min at the speed of 20000r/min, collecting supernatant, and freeze-drying at-80 ℃ to obtain the maggot.
The preparation process of the five-cereal worm amino acid extract comprises the following steps:
Placing 5g of aseptic larva of five-cereal insects into a mortar, adding 3mL of liquid nitrogen, fully grinding to obtain coarse powder, adding distilled water 10 times the amount of the coarse powder, extracting by a Soxhlet extraction method for 3 times, extracting for 2 hours each time, combining 3 times of extracting solutions, purifying by an ion exchange method, and drying to obtain the compound preparation.
The five-cereal insect extract is extracted from lucilia sericata, chrysomya megacephala, chrysomya erythropolis, nostoc trichina or other insect larvae near the lucilia trichina.
A pharmaceutical composition comprises a five-cereal insect protein extract, a five-cereal insect amino acid extract and auxiliary materials, wherein the mass ratio of the five-cereal insect protein extract to the five-cereal insect amino acid extract is 1:1-2.
The beneficial effects of the invention are as follows:
The application of the five-cereal insect extract in preparing the medicament for treating the digestive diseases provided by the invention has the advantages that the five-cereal insect protein extract and the five-cereal insect amino acid are used for treating peptic ulcer, irritable bowel syndrome, bacterial enteritis and viral enteritis, and the medicament effect is clear, safe and reliable.
The extraction process of the five-cereal insect protein extract and the five-cereal insect amino acid is not treated by an organic solvent, and the five-cereal insect protein extract and the five-cereal insect amino acid are free from toxic reagent pollution, safe and harmless, and belong to pure natural preparations; meanwhile, the components of the pharmaceutical composition are mainly natural proteins and amino acids, so that the pharmaceutical composition has no toxic or side effect and does not produce adverse reaction.
The invention prepares the medicament for treating digestive diseases caused by conditional pathogenic bacteria or viruses by separating main active components of the five-cereal insects, namely the five-cereal insect proteins and amino acid substances, and can also maintain the functional integrity of gastrointestinal mucosa so as to resist abdominal pain and bacteremia caused by exogenous pathogenic factors.
As will be described in further detail below.
Detailed Description
Further advantages and effects of the present invention will become apparent to those skilled in the art from the disclosure of the present specification, by describing the embodiments of the present invention with specific examples.
The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein, which are provided to disclose the invention in full and complete terms, and to fully convey the scope of the invention to those skilled in the art. The terminology used in the exemplary embodiments is not intended to be limiting of the invention.
Unless otherwise indicated, terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, it will be understood that terms defined in commonly used dictionaries should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense.
Example 1:
The embodiment provides application of the five-cereal worm extract in preparing a medicament for treating digestive diseases.
Compared with the existing chemical drugs, antibiotics and antiviral drugs used for clinically treating peptic ulcer, stress gastroenteritis, bacterial enteritis, viral enteritis and other digestive diseases, the five-cereal worm extract has small toxic and side effects and less adverse reactions.
Example 2:
on the basis of the embodiment 1, the embodiment provides application of the five-cereal insect extract in preparing a medicament for treating digestive diseases, wherein the five-cereal insect extract is a five-cereal insect protein extract and/or a five-cereal insect amino acid extract, the mass fraction of total protein in the five-cereal insect protein extract is 35-90%, and the mass fraction of total amino acid in the five-cereal insect amino acid extract is 40-95%.
The digestive diseases are peptic ulcer, stress gastroenteritis, bacterial enteritis or viral enteritis.
The preparation process of the five-cereal insect protein extract comprises the following steps:
Placing sterilized larva of five-cereal worms (5 g) into a mortar, adding about 3mL of liquid nitrogen, fully grinding, then adding 5mL of water solution containing 0.1 mug/mL aprotinin and 0.1% trifluoroacetic acid, fully grinding, centrifuging (20000 r/min,4 ℃ for 30 min) after light-shielding ice bath of the homogenate for 60min, collecting supernatant, heating in boiling water bath for 10min, centrifuging (20000 r/min,4 ℃ for 30 min), collecting supernatant, and freeze-drying at-80 ℃. The mass fraction of total protein in the five-cereal insect protein extract prepared in this example was 69.4%.
The preparation process of the five cereal worm amino acid extract comprises the following steps:
The aseptic maggot larva (5 g) is put into a mortar, liquid nitrogen is added for about 3mL, the mixture is fully crushed to obtain coarse powder, distilled water with the amount of 10 times of the coarse powder is added, and the mixture is extracted by a Soxhlet extraction method for 3 times, and each time is 2 hours. Mixing the 3 times of extractive solutions, purifying by ion exchange method, and drying. The mass fraction of total amino acids in the five-cereal worm amino acid extract prepared in the example is 86.9%.
Example 3:
This example is an experimental verification of the therapeutic effect of the five-cereal protein extract and the five-cereal amino acid extract prepared in example 2 on peptic ulcer.
1. Experimental method
Male Kunming mice (18-22 g) were purchased from Beijing vitamin Torilhua limited and randomly divided into a normal control group, an omeprazole group (2 mg/kg), a low-dose group of wuliangyptin extract (5 mg/kg), a high-dose group of wuliangyptin extract (10 mg/kg), a low-dose group of wuliangyptin amino acid extract (5 mg/kg), a high-dose group of wuliangyptin amino acid extract (10 mg/kg), and a total of five-cereal protein extract+wuliangyptin amino acid extract (1:1, 10 mg/kg), each group of 8 animals. The drug-treated group was given the corresponding drug by gavage every day for 7 days, no water was fed after 7 days, and 1 hour after the last administration, a gastric aspirin-ethanol solution (200 mg/kg of aspirin was dissolved in 40% ethanol) was gavaged, and the mice were sacrificed for 4 hours, and gastric tissues were collected. Gastric ulcer sites were observed under a dissecting microscope and scored according to lesion extent. Local hyperemia and redness are marked as 1 minute, punctiform bleeding or erosion are respectively marked as 1 minute, linear erosion is marked as 3 minutes, and the total score is used as an ulcer index. H +,K+ -ATPase enzyme activity in stomach tissue was determined using an ELISA kit.
2. Experimental results
Aspirin-ethanol solution resulted in smoother stomach wall, multiple ulcers, and larger ulcer areas, multiple bleeding points in the mice of the model group. The five-cereal insect protein extract and the five-cereal insect amino acid extract have folds on the inner wall of the stomach, the ulcer area is obviously reduced, the bleeding points are obviously reduced, and the gastric ulcer symptoms are obviously improved, so that the five-cereal insect protein extract and the five-cereal insect amino acid extract have definite anti-ulcer effect in an aspirin-induced mouse gastric ulcer model. Meanwhile, the combined effect of the five-cereal worm protein extract and the amino acid extract is better, and the five-cereal worm protein extract and the amino acid extract are obviously better than omeprazole, and the results are shown in Table 1.
Table 1 effects of wu-gu-worm protein extract and wu-gu-worm amino acid extract on aspirin-ethanol induced gastric ulcer model (n=8, mean±sd)
Note that: ## P <0.01vs blank; ** P <0.01vs model group.
Example 4:
In this example, the therapeutic effect of the five-cereal protein extract and the five-cereal amino acid extract prepared in example 2 on irritable bowel syndrome was experimentally verified.
1. The experimental method comprises the following steps:
SD rats (sex is unlimited, day 8 of birth) were purchased from Beijing velutinal Limited and randomly divided into a normal control group, a Pivern ammonium bromide (13.5 mg/kg) group, a five-cereal insect protein extract high dose group (14 mg/kg), a five-cereal insect protein extract low dose group (7 mg/kg), a five-cereal insect amino acid extract high dose group (14 mg/kg), a five-cereal insect amino acid extract low dose group (7 mg/kg), a five-cereal insect protein extract + five-cereal insect amino acid extract (1:1, 14 mg/kg), 8 animals per group. A rat model of visceral Gao Minxing irritable bowel syndrome is established by adopting a rectal distention stimulation method and a short-term separation method of a suckling mouse and a female mouse, after the female mouse and the suckling mouse are adaptively fed for 7 days, a 15mm balloon is inserted into the rectum of the suckling mouse, and water is gradually injected to distend the intestinal tract for 2 times/d, each time for 1min, and the duration is 5 days. Rectal dilation was performed with a 20mm balloon instead for 5d 13. The child urinary catheter was used instead to dilate the rectum for 4d at 18 d. After each expansion, the mice were placed in cages individually, separated from the mice for 1 hour, and then kept in the cages. Intestinal sensitivity was assessed by abdominal evacuation reflex at week 2, week 4 after modeling to confirm model success. After confirming molding, the corresponding drug was administered by gavage 1/d for 2 weeks. After the experiment is finished, weighing all rat weights; abdominal Withdrawal Reflex (AWR) capacity threshold detection; ELISA method for determining rat serum Vasoactive Intestinal Peptide (VIP) and Motilin (MTL) activities.
2. Experimental results
2.1 General State observations in rats
The rats in the model group have the advantages of irritability, reduced activity, turnera, reduced drinking water, reduced physical quality, poor mental state, slow response, dry and yellow hair color and thin and sticky feces. The activity of rats in the five-cereal worm protein extract, the five-cereal worm amino acid extract and the positive medicine group is increased, the spirit is recovered, the hair color is normal, the stool is normal, and the body quality is increased.
2.2 Rat AWR Capacity threshold comparison
As shown in table 2, compared to the blank group, the model group rats had a raised abdomen, significantly reduced back arch AWR capacity threshold (P < 0.01); compared with a model group, the capacity threshold values of the five-cereal insect protein extract and the five-cereal insect amino acid extract, such as abdomen lifting and back arching AWR, are increased (P < 0.01), and the high-dose group of the five-cereal insect protein extract and the five-cereal insect amino acid extract has dose dependency, compared with positive medicine pinaverium bromide, no significant difference exists, and the combined administration group of the five-cereal insect protein and the amino acid extract has better effect and is superior to that of the pinaverium bromide.
TABLE 2 influence of five cereal protein extracts and five cereal amino acid extracts on AWR Capacity threshold
Note that: ## P <0.01vs blank; ** P <0.01vs model group.
2.3 Rat serum Vasoactive Intestinal Peptide (VIP) and Motilin (MTL) Activity
As shown by the results in table 3, VIP and MTL levels were elevated in the serum of the model group and the differences were statistically significant (P < 0.01) compared to the blank group; compared with the model group, the VIP and MTL levels in the serum of the five-cereal insect protein extract and five-cereal insect amino acid extract treatment group were reduced, and the difference was statistically significant (P < 0.01). The high dose group of the five cereal worm protein extract and the five cereal worm amino acid extract has no significant difference compared with the positive drug, namely, the pinaverium bromide.
TABLE 3 Effect of five cereal protein extracts and five cereal amino acid extracts on VIP and MTL levels
Note that: ## P <0.01vs blank; ** P <0.01vs model group.
The results show that the five-cereal insect protein extract group and the five-cereal insect amino acid extract have definite treatment effects on irritable bowel syndrome, and the combined effect of the two is better.
Example 5:
In this example, the therapeutic effect of the five-cereal protein extract and the five-cereal amino acid extract prepared in example 2 on bacterial enteritis was experimentally verified.
1. The experimental method comprises the following steps:
SD rats (sex limitless, 160-180 g) were purchased from Beijing vitamin Toril Lihua Co., ltd, and after 7d of adaptive feeding, the experiment was started. The method is randomly divided into a normal control group, a model group, a sulfasalazine enteric coated tablet (225.5 mg/kg) group, a five-cereal insect protein extract high dose group (14 mg/kg), a five-cereal insect protein extract low dose group (7 mg/kg), a five-cereal insect amino acid extract high dose group (14 mg/kg), a five-cereal insect amino acid extract low dose group (7 mg/kg), and 8 five-cereal insect protein extract+five-cereal insect amino acid extract (1:1, 14 mg/kg). Except for normal group rats, the remaining rats were modeled for bacterial enteritis: e.coli bacterial antigen 0.2mL was injected at the hind plantarum of the first day, respectively; subcutaneous injections of 0.4mL and 0.6mL of bacterial antigen were given on the abdomen and back on days 10 and 17, respectively; 1.2mL of bacterial antigen was intraperitoneally injected on day 24 for a total of 4 immunizations. Rats were given 1.5mL of E.coli suspension (1X 10 9/mL) per rat lavage at 2 nd injection of bacterial antigen and corresponding drug 1 time daily for 14d before 3 rd injection of bacterial antigen. 24 hours after the last administration, serum was taken and the IL-1 beta, IL-10 and TNF-alpha content was determined, and specific operations were performed with reference to the kit instructions.
2. Experimental results:
As shown by the results in Table 4, the IL-1. Beta., IL-10 and TNF-. Alpha.levels in the serum of rats were elevated after E.coli infection, and the differences were statistically significant compared to the rats in the blank group. The five-cereal insect protein extract and the five-cereal insect amino acid extract can inhibit the IL-1 beta, IL-10 and TNF-alpha levels in serum, and compared with a model group, the difference has statistical significance, so that the five-cereal insect protein extract and the five-cereal insect amino acid extract have definite treatment effect on bacterial enteritis, and the combined effect of the two is better than that of a positive control medicine, namely the sulfasalazine enteric-coated tablet.
TABLE 4 influence of five cereal protein extracts and five cereal amino acid extracts on inflammatory factors in serum
Note that: ## P <0.01vs blank; ** P <0.01vs model group.
Example 6:
In this example, the therapeutic effect of the five-cereal worm protein extract and the five-cereal worm amino acid extract prepared in example 2 on viral enteritis was verified by experiments.
1. The experimental method comprises the following steps:
Clean-grade Kunming rats were purchased from Beijing velton Lihua limited and randomly divided into a normal control group, a model group, a negative control group, a high dose group of the five-cereal insect protein extract (14 mg/kg), a low dose group of the five-cereal insect protein extract (7 mg/kg), a high dose group of the five-cereal insect amino acid extract (14 mg/kg), a low dose group of the five-cereal insect amino acid extract (7 mg/kg), and 8 groups of the five-cereal insect protein extract+the five-cereal insect amino acid extract (1:1, 14 mg/kg). The negative control group was given 150. Mu.l of bacterial culture without rotavirus, the normal group was given physiological saline, and the model group and the drug-treated group were given 150. Mu.l of rotavirus containing 1X 10 4 TCID50 for gastric lavage. The drug-treated groups were given the five-cereal protein extract and the five-cereal amino acid extract 3 times daily, 50 μl each time, for 4 days by gavage at 24h and 48h, respectively, after virus inoculation. And observing physiological indexes such as diarrhea, activity ability and mental state of the suckling mice. Diarrhea of the suckling mice is scored, diarrhea is scored (0-4 points) according to the color, hardness, quantity and the like of the feces, no feces is discharged for 0 point, brown molded feces is scored for 1 point, brown soft feces is scored for 2 points, yellow soft feces is scored for 3 points, yellow thin water sample feces is scored for 4 points, perianal feces pollution is scored for 4 points, and diarrhea is considered to be the diarrhea after the stool pollution is greater than 2 points. The feces were resuspended in 10% PBS, the supernatant was centrifuged at 8000g/min and the viral antigen load in the feces was determined using rotavirus colloidal gold kit and ELISA, respectively.
2. Experimental results
2.1 General State
After rotavirus administration, the milk mice have obvious symptoms of diarrhea, listlessness, dull hair color, somnolence, weak motility and the like, and continue until experimental observation is finished, a large amount of feces are polluted around anus, and some mice have ulceration bleeding and no death. The five cereal protein extract and five cereal amino acid extract gastric lavage group show 4 and 3 infection symptoms on day 2 after infection, mainly showing diarrhea (light yellow water sample feces), and the diarrhea rate is 50% and 37.5%, respectively. On day 4, the diarrhea symptoms of the rats were significantly reduced, as indicated by yellow pasty stool, and the extra-intestinal symptoms were not apparent (table 5).
TABLE 5 influence of the five cereal protein extract and the five cereal amino acid extract on the degree of diarrhea
Note that: ## P <0.01vs blank; ** P <0.01vs model group.
2.2 Rotavirus detection results
Rotavirus positive conditions in feces are detected by using a rotavirus colloidal gold detection kit, and rotavirus antigen levels in feces are detected by using an ELISA kit. As shown in the results of Table 6, the positive rate of the rotavirus in the model group was 100%, and the positive rate was reduced to a different extent after administration of the drug, in particular, the positive rate was about 30% in the high dose group of the five-cereal worm protein extract, and the antigen level was significantly reduced to 9.66% in the model group, and similarly, the rotavirus antigen level was significantly reduced in the remaining five-cereal worm protein extract and five-cereal worm amino acid extract groups, and significantly different from that in the model group (P < 0.01). These evidence indicate that the maggot protein extract and maggot amino acid extract significantly reduced rotavirus infection ability.
TABLE 6 Effect of five cereal protein extracts and five cereal amino acid extracts on antigen levels
Note that: ## P <0.01vs blank; ** P <0.01vs model group.
The evidence shows that the five-cereal worm protein extract and the five-cereal worm amino acid extract have definite treatment effect on viral enteritis, and the combined effect of the two is better.
In conclusion, the five-cereal worm protein extract and the five-cereal worm amino acid extract have definite treatment effects on peptic ulcer, viral enteritis, bacterial enteritis and irritable bowel syndrome.
The foregoing examples are merely illustrative of the present invention and are not intended to limit the scope of the present invention, and all designs that are the same or similar to the present invention are within the scope of the present invention.
Claims (4)
1. The application of the five-cereal worm extract in preparing a medicament for treating digestive diseases is characterized in that: the five-cereal insect extract is a five-cereal insect protein extract and a five-cereal insect amino acid extract, wherein the mass fraction of total protein in the five-cereal insect protein extract is 35-90%, and the mass fraction of total amino acid in the five-cereal insect amino acid extract is 40-95%;
the mass ratio of the five cereal insect protein extract to the five cereal insect amino acid extract is 1:1-2;
The digestive diseases are peptic ulcer, irritable bowel syndrome, bacterial enteritis or viral enteritis; the preparation process of the five-cereal insect protein extract comprises the following steps:
Putting 5g of aseptic maggot larva into a mortar, adding 3mL of liquid nitrogen, fully grinding, adding 5mL of water solution containing 0.1 mug/mL aprotinin and 0.1% trifluoroacetic acid, fully grinding, centrifuging the homogenate at 4 ℃ for 30min after being subjected to light-proof ice bath for 60min at the speed of 20000r/min, collecting supernatant, heating in a boiling water bath for 10min, centrifuging at 4 ℃ for 30min at the speed of 20000r/min, collecting supernatant, and freeze-drying at-80 ℃ to obtain the compound;
the preparation process of the five-cereal worm amino acid extract comprises the following steps:
Placing 5g of aseptic larva of five-cereal insects into a mortar, adding 3mL of liquid nitrogen, fully grinding to obtain coarse powder, adding distilled water 10 times the amount of the coarse powder, extracting by a Soxhlet extraction method for 3 times, extracting for 2 hours each time, combining 3 times of extracting solutions, purifying by an ion exchange method, and drying to obtain the compound preparation.
2. Use of a five-cereal worm extract according to claim 1 for the preparation of a medicament for the treatment of digestive disorders, characterized in that: the five cereal worm protein extract and the five cereal worm amino acid extract are mixed with auxiliary materials to prepare the oral preparation.
3. Use of a five cereal worm extract according to any one of claims 1-2 for the preparation of a medicament for the treatment of digestive disorders, characterized in that: the five-cereal worm extract is extracted from larvae of lucilia sericata and Chrysomya megacephala.
4. A pharmaceutical composition characterized by: the five-cereal worm protein extract comprises a five-cereal worm protein extract, a five-cereal worm amino acid extract and auxiliary materials, wherein the mass fraction of total protein in the five-cereal worm protein extract is 35-90%, the mass fraction of total amino acid in the five-cereal worm amino acid extract is 40-95%, and the mass ratio of the five-cereal worm protein extract to the five-cereal worm amino acid extract is 1:1-2;
the preparation process of the five-cereal insect protein extract comprises the following steps:
Putting 5g of aseptic maggot larva into a mortar, adding 3mL of liquid nitrogen, fully grinding, adding 5mL of water solution containing 0.1 mug/mL aprotinin and 0.1% trifluoroacetic acid, fully grinding, centrifuging the homogenate at 4 ℃ for 30min after being subjected to light-proof ice bath for 60min at the speed of 20000r/min, collecting supernatant, heating in a boiling water bath for 10min, centrifuging at 4 ℃ for 30min at the speed of 20000r/min, collecting supernatant, and freeze-drying at-80 ℃ to obtain the compound;
the preparation process of the five-cereal worm amino acid extract comprises the following steps:
Placing 5g of aseptic larva of five-cereal insects into a mortar, adding 3mL of liquid nitrogen, fully grinding to obtain coarse powder, adding distilled water 10 times the amount of the coarse powder, extracting by a Soxhlet extraction method for 3 times, extracting for 2 hours each time, combining 3 times of extracting solutions, purifying by an ion exchange method, and drying to obtain the compound preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210525727.6A CN114796283B (en) | 2022-05-16 | Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210525727.6A CN114796283B (en) | 2022-05-16 | Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114796283A CN114796283A (en) | 2022-07-29 |
| CN114796283B true CN114796283B (en) | 2024-07-05 |
Family
ID=
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110279720A (en) * | 2019-07-31 | 2019-09-27 | 浙江佰科堂生物科技股份有限公司 | A kind of maggot processed product and its application in adjusting intestinal flora |
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110279720A (en) * | 2019-07-31 | 2019-09-27 | 浙江佰科堂生物科技股份有限公司 | A kind of maggot processed product and its application in adjusting intestinal flora |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| CN110893194B (en) | New application of bifidobacterium lactis BL-99 in inhibiting intestinal inflammation | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN111265650A (en) | Novel traditional Chinese medicine composition and preparation method thereof | |
| CN102973829B (en) | Feed for treating diarrhea of dairy cow | |
| CN114796283B (en) | Application of five-cereal worm extract in preparation of medicine for treating digestive diseases and pharmaceutical composition | |
| CN116966206A (en) | Use of lactobacillus fermentum for the preparation of a product for the prevention and/or treatment of the colon of a laxative | |
| CN113413454A (en) | Composition for promoting gastric mucosa injury repair and preparation method thereof | |
| CN105902558B (en) | A kind of pharmaceutical composition and its preparation method and application | |
| CN115216423B (en) | Bifidobacterium animalis SF and application thereof in medicines and foods | |
| CN107362292A (en) | It is a kind of that there is the composition for improving female genitourinary system inflammation, preparation method and application | |
| CN104042879B (en) | Traditional Chinese medicine granules for reversing precancerous lesions of chronic atrophic gastritis and preparation method thereof | |
| CN108853081B (en) | Application of amentoflavone in preparation of medicine for treating necrotic enteritis of chicken | |
| CN114796283A (en) | Application of maggot extract in preparing medicine for treating digestive diseases and pharmaceutical composition | |
| CN106619745A (en) | Biological bacteria liquid for treating gastrointestinal diseases and preparation method of biological bacteria liquid | |
| CN114533750B (en) | Application of pericarpium Granati tannin in preparing medicine for treating enterotoxigenic escherichia coli intestinal diseases | |
| CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof | |
| CN109260297B (en) | A Chinese medicinal composition for treating hemorrhoid, and its preparation method | |
| CN106938041A (en) | It is a kind of to treat Chinese medicine preparation of gastric ulcer and preparation method thereof and its medicinal usage | |
| CN116803300A (en) | Synbiotic composition capable of improving chronic constipation symptom and preparation method and application thereof | |
| CN113559215A (en) | Medicine for improving human body excretion and its preparation method | |
| CN114533750A (en) | Application of pomegranate bark tannin in preparation of medicine for treating enterotoxigenic escherichia coli intestinal diseases | |
| CN116098225A (en) | Functional food for curing chronic colitis | |
| CN118267434A (en) | Traditional Chinese medicine composition for treating acute lower gastrointestinal hemorrhage combined with intestinal flora disorder and application thereof | |
| CN105213653A (en) | The traditional Chinese medicine emulsifiable paste of a kind of obstetrics prevention cesarean postoperate fat liquefaction of abdominal incision |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |